Welcome to our dedicated page for Editas Medicine SEC filings (Ticker: EDIT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Editas Medicine, Inc. (Nasdaq: EDIT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a clinical-stage gene editing company focused on in vivo CRISPR/Cas12a and CRISPR/Cas9 medicines, Editas uses current reports on Form 8-K and other periodic filings to communicate material events, program updates, collaborations, and financial results to investors.
Through its 8-K filings, Editas Medicine furnishes press releases announcing quarterly financial results, cash runway expectations, and business highlights. These documents describe research and development expenses, collaboration and other research revenues, restructuring and impairment charges, and the company’s view of its ability to fund operating expenses and capital expenditure requirements over a multi-year period. They also outline key risk considerations and refer readers to the company’s Annual Report on Form 10-K and subsequent filings for detailed risk factors.
Filings also summarize important scientific and pipeline milestones. For example, Editas has used 8-K reports to describe the nomination of EDIT-401 as its lead in vivo development candidate for hyperlipidemia, preclinical proof-of-concept data demonstrating approximately 90% LDL-C reduction in non-human primates and mice, and the therapeutic strategy of using CRISPR/Cas9 with dual guide RNAs and lipid nanoparticle delivery to upregulate LDLR. Other filings discuss in vivo proof-of-concept data for EDIT-401 presented at major gene and cell therapy conferences.
Investors can review these SEC filings to understand how Editas Medicine reports the status of its in vivo HSC program for sickle cell disease and beta thalassemia, its collaboration with Bristol Myers Squibb on T cell medicines, and payments under its license agreement with Vertex Pharmaceuticals. On Stock Titan, AI-powered tools can help summarize lengthy filings, highlight key sections related to EDIT-401, cash runway, collaborations, and program changes, and make it easier to interpret complex technical and financial disclosures without reading every line of each document.
Editas Medicine reported a Q1 2026 net loss of $25.0 million, sharply improved from $76.1 million a year earlier as prior restructuring and impairment charges rolled off and operating costs declined.
Collaboration and other R&D revenue fell to $2.8 million from $4.7 million. Research and development expense dropped to $17.6 million and general and administrative expense to $10.2 million, reflecting the discontinuation of the reni‑cel program and a large workforce reduction completed in 2025.
The company ended March 31, 2026 with $123.6 million in cash and cash equivalents and an accumulated deficit of about $1.7 billion. Management states this cash should fund operations into the third quarter of 2027 while Editas advances lead in vivo gene‑editing candidate EDIT‑401 toward first‑in‑human studies and early proof‑of‑concept data.
Editas Medicine reported first quarter 2026 results and highlighted progress on its lead in vivo gene-editing program, EDIT-401, for hyperlipidemia and HeFH. Preclinical data showed more than 90% mean LDL-C reduction, and the company plans to start a first-in-human trial in 2026 with early proof-of-concept data expected by year-end and dose-finding topline data in 2027.
Cash and cash equivalents were $123.6 million as of March 31, 2026, which the company expects will fund operations into the third quarter of 2027. Net loss narrowed to $25.0 million, or $0.26 per share, compared with a net loss of $76.1 million, or $0.92 per share, a year earlier, driven by lower R&D and G&A expenses and the absence of prior-year restructuring and impairment charges.
Collaboration and other research and development revenues were $2.8 million, down from $4.7 million in the prior-year quarter, primarily because 2025 included remaining deferred revenue recognized when a collaboration ended. The U.S. Patent and Trademark Office also reaffirmed a prior Patent Trial and Appeal Board decision favoring the Broad Institute in a CRISPR/Cas9 interference involving patents exclusively licensed to Editas for use in human cells.
Editas Medicine filed its Annual Report on Form 10-K reporting continued focus on in vivo CRISPR gene editing and the nomination of its lead candidate, EDIT-401, an in vivo LDLR upregulation program that produced ~90% mean LDL-C reductions in non-human primates. The company plans an IND or foreign equivalent for EDIT-401 by mid-2026, expects early human proof-of-concept by the end of 2026, and topline dose-finding results in 2027. The report discloses 97,871,999 shares outstanding as of February 27, 2026 and an aggregate market value held by non-affiliates of approximately $191,377,146 as of June 30, 2025. The filing restates strategic priorities: advance EDIT-401, continue HSC and extrahepatic LNP work, and monetize IP via collaborations and licenses.
Editas Medicine has issued its definitive proxy statement for the 2026 virtual annual meeting on June 17, 2026, where stockholders will elect two Class I directors, cast an advisory vote on executive pay, and ratify PricewaterhouseCoopers as auditor.
The company highlights its strategic shift to a fully in vivo gene editing preclinical model, including lead candidate EDIT-401 for LDL‑cholesterol with preclinical LDL‑C reductions exceeding 90% in non‑human primates. Management reports extending its cash runway into the third quarter of 2027, supported in part by an at‑the‑market offering program.
Governance and pay practices emphasize board independence, a separate chair and CEO, annual say‑on‑pay, anti‑hedging and clawback policies, and substantial performance-based pay, with approximately 73% of CEO target compensation and 54% of other named executive officer target compensation designated as performance-based. The board determined 2025 corporate objectives were achieved at 91% of target for bonus purposes and is recommending stockholders vote in favor of all three proposals.
Editas Medicine, Inc. has replaced its long-time auditor, dismissing Ernst & Young LLP and appointing PricewaterhouseCoopers LLP as its new independent registered public accounting firm for the fiscal year ending December 31, 2026.
The Audit Committee made the change after soliciting proposals and conducting a formal review. Ernst & Young’s audit reports for 2024 and 2025 contained no adverse opinions or qualifications, and the company reports no disagreements or reportable events with Ernst & Young through April 1, 2026.
Editas Medicine announced that the U.S. Patent and Trademark Office has reaffirmed the Patent Trial and Appeal Board’s prior decision favoring the Broad Institute in a key CRISPR/Cas9 patent interference covering gene editing in human cells. This is the PTAB’s third favorable decision confirming Broad as first to invent CRISPR/Cas9 use in eukaryotic cells.
The CRISPR/Cas9 patents at issue are exclusively licensed to Editas for developing and commercializing CRISPR/Cas9-based medicines, underpinning its gene editing pipeline. Other in-licensed Broad, Harvard, MIT and collaborator patents, including CRISPR/Cas12a rights, are not involved in this interference and remain unaffected.
Management highlighted this outcome as reinforcing confidence in the company’s intellectual property as it advances in vivo gene editing programs, including EDIT-401, an experimental one-time therapy that has achieved greater than 90 percent mean LDL cholesterol reduction in non-human primates. CVC parties retain the right to appeal the decision to the Federal Circuit.
The Vanguard Group filed an amendment (Schedule 13G/A) reporting that it beneficially owns 0 shares of Editas Medicine common stock, representing 0% of the class. The filing explains an internal realignment on January 12, 2026 that led certain Vanguard subsidiaries to report holdings separately.
Editas Medicine, Inc. reported that CEO O'Neill Gilmore Neil received a grant of stock options covering 1,015,200 shares of common stock at an exercise price of $2.54 per share. The options were granted as compensation and have no purchase price at grant.
The award is scheduled to vest over four years in equal monthly installments, beginning on April 12, 2026 and continuing through March 12, 2030, aligning the CEO’s long-term incentives with company performance over that period.
Editas Medicine, Inc. reported that its SVP and Chief Financial Officer, Amy Parison, received a grant of stock options covering 292,856 shares of common stock. The options have an exercise price of $2.54 per share and were granted as a compensation award, not an open-market purchase.
According to the disclosure, the options were granted on March 12, 2026 and are scheduled to vest over four years in equal monthly installments from April 12, 2026 through March 12, 2030. Following this award, she holds 292,856 option-based rights to acquire Editas Medicine common shares directly.
Editas Medicine, Inc. reported that EVP and Chief Scientific Officer Linda Burkly received a grant of stock options covering 292,856 shares of common stock. The options have an exercise price of $2.54 per share and expire on March 11, 2036.
The award was granted on March 12, 2026 and is scheduled to vest over four years in equal monthly installments from April 12, 2026 through March 12, 2030. Following this grant, Burkly holds 292,856 stock options from this award.